$1.99 Million is the total value of FRAZIER MANAGEMENT LLC's 2 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 95.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRRA | Sell | SIERRA ONCOLOGY INC | $1,752,000 | -93.6% | 54,654 | -95.7% | 88.13% | +4062.9% |
| ALNA | Sell | ALLENA PHARMACEUTICALS | $236,000 | -75.9% | 1,019,288 | -38.3% | 11.87% | +15728.0% |
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -425,650 | -100.0% | -0.02% | – | |
| EPZM | Exit | EPIZYME INC | $0 | – | -739,369 | -100.0% | -0.14% | – |
| SRRK | Exit | SCHOLAR ROCK HLDG CORP | $0 | – | -156,000 | -100.0% | -0.30% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -585,759 | -100.0% | -0.38% | – |
| APTX | Exit | APTINYX INC | $0 | – | -1,883,244 | -100.0% | -0.39% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -1,374,047 | -100.0% | -0.42% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -408,329 | -100.0% | -0.46% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -951,814 | -100.0% | -0.59% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -235,809 | -100.0% | -0.59% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -543,470 | -100.0% | -0.59% | – |
| GRCL | Exit | GRACELL BIOTECHNOLOGIES INCsponsored ads | $0 | – | -1,654,938 | -100.0% | -0.77% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -163,763 | -100.0% | -1.04% | – |
| FLACU | Exit | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $0 | – | -1,501,000 | -100.0% | -1.15% | – |
| COGT | Exit | COGENT BIOSCIENCES INC | $0 | – | -1,774,891 | -100.0% | -1.17% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -1,783,893 | -100.0% | -1.31% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -1,305,087 | -100.0% | -1.33% | – |
| Exit | TYRA BIOSCIENCES INC | $0 | – | -1,250,000 | -100.0% | -1.35% | – | |
| REPL | Exit | REPLIMUNE GROUP INC | $0 | – | -650,862 | -100.0% | -1.36% | – |
| MRUS | Exit | MERUS N V | $0 | – | -559,179 | -100.0% | -1.37% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -3,746,857 | -100.0% | -1.50% | – |
| SLN | Exit | SILENCE THERAPEUTICS PLCads | $0 | – | -886,173 | -100.0% | -1.63% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -1,784,913 | -100.0% | -1.90% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -1,776,479 | -100.0% | -2.04% | – |
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -1,505,200 | -100.0% | -2.29% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -1,838,402 | -100.0% | -2.37% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -899,700 | -100.0% | -2.41% | – |
| PASG | Exit | PASSAGE BIO INC | $0 | – | -5,009,219 | -100.0% | -2.45% | – |
| TARS | Exit | TARSUS PHARMACEUTICALS INC | $0 | – | -1,417,157 | -100.0% | -2.46% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -1,747,622 | -100.0% | -2.57% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -555,240 | -100.0% | -2.60% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -2,371,918 | -100.0% | -2.98% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -1,384,293 | -100.0% | -3.03% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -2,457,507 | -100.0% | -3.10% | – | |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -771,250 | -100.0% | -4.15% | – |
| PCVX | Exit | VAXCYTE INC | $0 | – | -2,309,554 | -100.0% | -4.23% | – |
| MIRM | Exit | MIRUM PHARMACEUTICALS INC | $0 | – | -3,566,912 | -100.0% | -4.38% | – |
| GRTS | Exit | GRITSTONE BIO INC | $0 | – | -4,667,242 | -100.0% | -4.62% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -2,772,062 | -100.0% | -4.67% | – |
| Exit | IMAGO BIOSCIENCES INC | $0 | – | -2,971,274 | -100.0% | -5.42% | – | |
| PHAT | Exit | PHATHOM PHARMACEUTICALS INC | $0 | – | -5,827,415 | -100.0% | -8.82% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -8,434,232 | -100.0% | -13.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.